Details

Autor(en) / Beteiligte

• Saxena, Sandeep
• Singh, Malvika
• Chaubey, Anupriya
• Mohan, Akshay
• De, Somnath
• Kaur, Apjit
• Gilhotra, Jagjit S
• Meyer, Carsten H
• Akduman, Levent

Titel

Anti-Vegf therapy leads to an improvement in grade of retinal pigment epithelium alterations on single layer retinal pigment epithelium map in diabetic macular edema

Ist Teil von

• European journal of ophthalmology, 2023-05, Vol.33 (3), p.1412-1417

Ort / Verlag

London, England: SAGE Publications

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose In bovine retinal pigment epithelium (RPE) cells, increased secretion of vascular endothelial growth factor (VEGF) has a positive linear association with proliferation of RPE. Spectral domain optical coherence tomography (SD-OCT) based improvement in grades of topographic retinal pigment epithelium alterations (RPE-A), were evaluated after intravitreal anti-VEGF therapy, in diabetic macular edema (DME), for the first time. Methods A tertiary care center-based, prospective study. Forty-four consecutive patients, 40–65 years of age with type 2 diabetes mellitus (DM) with DME, were administered three doses of anti-VEGF therapy at monthly intervals. Pre- and post-intervention SD-OCT was done and central sub field thickness (CST), cube average thickness (CAT) and topographic grades of RPE-A were assessed using single layer RPE map (SL-RPE) as; Grade 0: No alterations, Grade 1: Alteration in two quadrants, Grade 2: Alteration in more than two quadrants. Results CST decreased from 354.2 ± 16.0 µm pre-intervention to 233.2 ± 7.9 µm post-intervention. CAT reduced from 340.6 ± 6.5 µm pre-intervention to 274.1 ± 5.1 µm post-intervention. Significant improvement in grades of RPE-A pre- v/s post-intervention were observed. (Grade 0: 0 v/s 39; Grade 1: 17 v/s 3; Grade 2: 27 v/s 2) (p < 0.001). Conclusion Anti-VEGF therapy is associated with an improvement in grades of RPE-A in DME. The study was registered with the Clinical Trial Registry of India (CTRI/2019/03/018135).